N-[2-(1,3-benzoxazol-2-yl)phenyl]-4-methylbenzenesulfonamide | 42143-49-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(1,3-benzoxazol-2-yl)phenyl]-4-methylbenzenesulfonamide
• CAS: 42143-49-7
• 化学式: C₂₀H₁₆N₂O₃S
• 分子量: 364.4
• InChiKey: XKFNOBGOFBCSSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Organic electroluminescent element material and organic electroluminescent element
  申请人：——

  公开号：US20030138663A1

  公开（公告）日：2003-07-24

  This invention relates to a low-molecular-weight compound which is soluble in solvents and useful for a luminescent material and to an organic electroluminescent element (EL element) which comprises said luminescent material in its electroluminescent layer. The EL element comprises an EL material represented by the following formula (1) between electrodes at least one of which is transparent. 1 In formula (1), Ar 1 is a group represented by the following formula (2), Ar 2 is a group represented by the following formula (3) or (4) and Ar 1 and Ar 2 may condense to form a 10-membered ring in case Ar 2 is represented by the following formula (3) 2 wherein R 1 -R 4 and R 5 are hydrogen, alkyl, aryl and the like, Z is a divalent or trivalent metal such as zinc, aluminum, copper, beryllium, ruthenium, cobalt, rhodium, iridium and platinum and n is 2 or 3.

  本发明涉及一种低分子量化合物，其可溶于溶剂且用于发光材料，并涉及一种有机电致发光元件（EL元件），其在其电致发光层中包含所述发光材料。该EL元件在至少一个透明电极之间包含由以下式（1）表示的EL材料。 式（1）中，Ar1是由以下式（2）表示的基团，Ar2是由以下式（3）或（4）表示的基团，且当Ar2由以下式（3）表示时，Ar1和Ar2可缩合形成10元环。其中，R1-R4和R5是氢、烷基、芳基等，Z是二价或三价金属，例如锌、铝、铜、铍、钌、钴、铑、铱和铂，n为2或3。
• ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL
  申请人：Tsai Li-Huei

  公开号：US20100075926A1

  公开（公告）日：2010-03-25

  The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.
• US6790540B2
  申请人：——

  公开号：US6790540B2

  公开（公告）日：2004-09-14
• [EN] ACTIVATIQN OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL<br/>[FR] L'ACTIVATION DE L'HISTONE DÉSACÉTYLASE 1 (HDAC1) PROTÈGE CONTRE DES LÉSIONS DE L'ADN ET AUGMENTE LA SURVIE NEURONALE
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2010011318A2

  公开（公告）日：2010-01-28

  The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDACl activators. Exemplary HDACl activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5- chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.